

Open camera or QR reader and
scan code to access this article
and other resources online.



PROTOCOLS ARTICLE

A Combined Western and Bead-Based Multiplex Platform to Characterize Extracellular Vesicles

Josette C. van Maanen, MSc,¹ Frances C. Bach, Dr.,¹ Theresa S. Braun, Dr.,²
Alberta Giovanazzi, MSc,³ Bas W.M. van Balkom, Dr.,⁴ Markus Templin, Dr.,^{2,5}
Marca H.M. Wauben, Prof. Dr.,³ and Marianna A. Tryfonidou, Prof. Dr.¹

In regenerative medicine, extracellular vesicles (EVs) are considered as a promising cell-free approach. EVs are lipid bilayer-enclosed vesicles secreted by cells and are key players in intercellular communication. EV-based therapeutic approaches have unique advantages over the use of cell-based therapies, such as a high biological, but low immunogenic and tumorigenic potential. To analyze the purity and biochemical composition of EV preparations, the International Society for Extracellular Vesicles (ISEV) has prepared guidelines recommending the analysis of multiple (EV) markers, as well as proteins coisolated/recovered with EVs. Traditional methods for EV characterization, such as Western blotting, require a relatively high EV sample/protein input for the analysis of one protein. We here evaluate a combined Western and bead-based multiplex platform, called DigiWest, for its ability to detect simultaneously multiple EV markers in an EV-containing sample with inherent low protein input. DigiWest analysis was performed on EVs from various sources and species, including mesenchymal stromal cells, notochordal cells, and milk, from human, pig, and dog. The study established a panel of nine antibodies that can be used as cross-species for the detection of general EV markers and coisolates in accordance with the ISEV guidelines. This optimized panel facilitates the parallel evaluation of EV-containing samples, allowing for a comprehensive characterization and assessment of their purity. The total protein input for marker analysis with DigiWest was 1 µg for all nine antibodies, compared with ~10 µg protein input required for traditional Western blotting for one antibody. These findings demonstrate the potential of the DigiWest technique for characterizing various types of EVs in the regenerative medicine field.

Keywords: DigiWest technology, extracellular vesicles, protein markers, multiplex characterization

Impact Statement

In regenerative medicine, extracellular vesicles (EVs) have gained attention as a cell-free approach because of their high biological and low immunogenic/tumorigenic potential. We here explored a multiplex bead-based Western blot technique (DigiWest) for the characterization of EV preparations from different sources and species with regenerative potential. Using

¹Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.

²NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.

³Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.

⁴Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, the Netherlands.

⁵NMI TT Pharmservices, Berlin, Germany.

this technology, which can simultaneously detect many different proteins in a single EV sample and requires low total protein input, we established a panel of nine antibodies that can be used for cross-species EV preparations analysis. As such, the DigiWest technology might facilitate the translation of EV-based regenerative approaches.

Introduction

WITHIN THE FIELD OF CELL-BASED THERAPIES, different approaches apply, such as the transplantation of tissue-specific cells¹ or the application of stem cells (e.g., mesenchymal stromal cells [MSCs]²). Their clinical application is, however, limited due to the complicated regulatory pathways for cell therapies³ and the inherent high costs.⁴ To overcome this, universal donor-derived cells (e.g., allogenic)⁵ can be used, but as major drawback this can elicit an immune response in the patient. Although several strategies are developed to reduce these responses, none successfully ensure long-term survival of grafted cells.⁶

A promising cell-free alternative is the use of extracellular vesicles (EVs).⁷ EVs are lipid bilayer-enclosed vesicles secreted by cells under both physiological and pathological conditions.^{8–10} They play an important role in intercellular signaling, thereby influencing the behavior of target cells (e.g., cell phenotype, proliferation, and differentiation).⁷ EVs in regenerative medicine are of special interest, since EVs derived from regenerative stem cell populations harness a similar biological activity as the parent cell, but are considered to have no tumorigenic potential.^{7,11} The immunogenicity of EVs is, in contrast to that of cells, considered to be minimal, even when they are added from an allogenic source.^{12–14} Altogether, these unique advantages make EVs an attractive alternative to cell therapies.

Before EVs can be applied in a clinical setting, there are several bottlenecks with regard to the biochemical composition and the purity of EV preparations.¹⁵ EVs are commonly isolated from biological fluids or conditioned culture medium (CM).¹⁶ Besides a wide plethora of different EV types, these sources contain other colloidal structures such as cells, proteins, and lipoprotein particles.^{17,18} To assess the purity of EV preparations and to ensure that the observed effects are EV-mediated, characterization of EV samples is essential.^{18,19}

The International Society for Extracellular Vesicles (ISEV) has published guidelines for EV characterization recommending a list of protein markers to demonstrate the lipid bilayer structure of EVs (e.g., transmembrane or glycosylphosphatidylinositol-anchored proteins) and to identify luminal protein cargo (e.g., soluble cytosolic proteins). Furthermore, suggestions are made to analyze proteins that might be coisolated/recovered with EVs.¹⁹

The most commonly used method for characterization of EV markers is Western blotting²⁰ typically requiring >10 µg of protein for the detection of a single marker.²¹ For MSC-EVs, this translates to culture of 2–10 million MSCs, depending on the tissue source, harvesting time, and isolation method used for the MSC-EVs.^{22,23} This implies that the analysis of multiple markers for EV characterization using Western blotting requires a relatively high amount of EV sample input and is time consuming.²¹ A recently developed alternative for EV characterization is a bead-based Western blotting technique called DigiWest.²⁴

DigiWest uses a combination of Western blot and a bead-based microarray platform to allow the parallel identifica-

tion of multiple markers. DigiWest has shown a comparable sensitivity to Western blot, but requires one-hundredth of a traditional Western blotting sample lane for the detection of one marker, displaying its potential use for low protein samples. It has been successfully used to identify proteins in cell lysates.²⁴ This study aims to perform EV characterization based on the ISEV guidelines using DigiWest.

To show the potential of the technique, a spectrum of EVs relevant in regenerative medicine was characterized, involving EV-containing samples from different sources and species. Human MSC-EVs isolated from conditioned cell CM²⁵ (well characterized by other techniques²⁶) were included in this study. Furthermore, EVs derived from CM of pig and dog notochordal cell (NC)-rich tissue, known to contain EVs with regenerative potential²⁷ for patients suffering from low back pain due to intervertebral disk degeneration,²⁸ were used.

Lastly, EVs isolated from a complex biological fluid (human milk) were incorporated in the analysis. Milk-derived EVs have strong immune modulatory and anti-inflammatory effects.²⁹ These characteristics and their ability to be administered orally triggered the interest in the therapeutic use of milk-EVs in chronic and degenerative inflammatory disease.³⁰

Methods

DigiWest technology

DigiWest was performed as described previously²⁴ (Fig. 1). In brief, gel electrophoresis and Western blotting were performed using the NuPAGE system (Life Technologies) with a 4–12% Bis-Tris gel and polyvinylidene fluoride membranes. All proteins were biotinylated on the blot membrane and blots were washed in phosphate buffered saline (PBS) containing 0.1% Tween-20 (PBST) and dried overnight. Each lane was cut into 96 stripes of 0.5 mm and sorted into a 96-well plate (Greiner Bio-One).

After protein elution in 10 µL of 8 M urea in 100 mM Tris-HCl (pH 9.5) including 1% Triton-X100, neutravidin coated color-coded MagPlex beads (Luminex) were added. After overnight coupling, leftover coupling sites were blocked with deactivated NHS-PEG12-biotin (500 µM, 1 h). The DigiWest beads were pooled and the original sample lane was reconstructed by reassigning the color IDs of the MagPlex beads to the molecular weight (MW) fraction.

DigiWest beads were blocked in assay buffer (ELISA blocking reagent) supplemented with 0.2% milk powder, 0.05% Tween-20, and 0.02% sodium azide in a 96-well plate (Corning). Beads were incubated in 30 µL primary antibody (Supplementary Table S1) at 15°C overnight. After washing twice with PBST, R-phycoerythrin-conjugated secondary antibody (Supplementary Table S2) was added for 1 h at 23°C. Then, beads were washed twice with PBST and readout was performed on a Luminex FlexMAP 3D instrument.

For peak identification and quantification of the antibody-specific signals, the DigiWest analysis tool²⁴ was employed. This tool uses the 96 values for each initial lane obtained from the Luminex measurements on the 96 MW fractions and




FIG. 1. Schematic representation of DigiWest technology workflow. Comparable with standard Western blotting, proteins are separated by gel electrophoresis and transferred to a blotting membrane. The membrane is cut horizontally into strips representing molecular weight fractions. After protein solubilization, distinct color-coded Neutravidin-coated Luminex bead sets are added. The colored Luminex beads are pooled and an aliquot of the bead pool is used for incubation with primary antibodies. After the addition of secondary antibody, the sample is read on a Luminex instrument. The obtained signals are visualized as peaks of fluorescence when plotted against the molecular weight fractions. Color images are available online.

calculates a baseline using the bead background (e.g., empty beads measured on the Luminex) and secondary antibody-specific signal (e.g., bead incubation with species-specific antibody only). After subtraction of the background, the tool identifies the peaks at the appropriate MW and integrates the peaks. The reported values present the peak-specific fluorescence intensity (accumulated fluorescence intensity [AFI]).

Experiment Design

EVs were isolated from CM (MSC-EVs and NC-EVs) and a complex biological fluid (milk-EVs) (Fig. 2).

MSC culture, characterization, and generation of human MSC-derived EVs

Bone marrow-derived MSCs were derived by the UMC Utrecht Gene and Cell Therapy facility from three independent production batches from anonymous human donors upon written consent. MSCs were expanded in Dulbecco's Alpha MEM (ThermoFisher Scientific) supplemented with 10% fetal calf serum (FCS; Biowest), 100 U/mL penicillin, 100 µg/mL streptomycin, 0.1 µg/mL primocin, 200 µM L-ascorbic acid (Sigma), and 1 ng/mL basic fibroblast growth factor (ThermoFisher Scientific).³¹

The characterization of these MSCs with regard to the CD marker profile and their ability to differentiate into different lineages has been reported previously.³² To generate EVs, MSCs were grown to 80% confluency, whereafter the expansion medium was replaced for medium without FCS and primocin. After 24 h, CM was harvested and processed further for EV isolation.

Generation of pig and dog NC-derived EVs

EVs were isolated from healthy NC-rich intervertebral discs (Thompson grade I³³) of six pig and three dog donors. Whole pig spines (3 months old) were collected from the local slaughterhouse in accordance with national regulations. Dog spines (18 months old) were collected from

mixed breed dogs that were euthanized in unrelated research studies (AVD1080020173964). Intervertebral discs were opened under sterile conditions and NC-rich nucleus pulposus (NP) tissue was collected. NC-rich NP tissue and NCs, isolated as described previously,³⁴ were employed as positive control samples for DigiWest.

For NC-EV generation, CM was generated by culturing NC-rich tissue for 4 days (1 g tissue/30 mL medium) in HgDMEM+Glutamax (31966; Gibco) with 1% Penicillin-Streptomycin (15140122; Gibco) at 37°C, 5% CO₂, and 5% O₂ as described previously.³⁵ After 4 days, the CM was filtered through a 70 µm cell strainer and thereafter processed for EV isolation.

EV isolation from NC- and MSC-CM

EVs present in CM from NCs and MSCs were purified through differential centrifugation and size exclusion chromatography (SEC) (Fig. 2) as described previously.²⁷ NC-CM was centrifuged twice sequentially at 200 and 500 g (10 min, 4°C) to remove cells. MSC-CM was centrifuged once at 1500 g for 15 min. The supernatant was concentrated 15 times (MSC-CM and dog NC-CM) or 5 times (pig NC-CM) using a 3 kDa Amicon Ultra-15 centrifugal filter tube at 3214 g at 4°C for the required time, until ~500 µL was left in the filter (2–5 h).

All substances with an MW >3 kDa were resuspended in 1 mL PBS (Gibco; 10010023). To remove remaining cellular debris and apoptotic bodies, the concentrated CM was centrifuged at 10,000 g (4°C, 35 min). The supernatant was aliquoted and stored at –80°C until further use.

For SEC, qEV SEC-columns (iZON Science; 1 mL sample/column) were calibrated and eluted with PBS (Gibco; 10010023). For each sample, 25 fractions of 0.5 mL were collected per qEV column (MSC-derived EVs: 8 columns; dog NC-derived EVs: 1 column; pig NC-derived EVs: 6 columns). The protein concentration of each fraction was determined at 280 nm (DeNovix; DS-11).

Based on the expected EV sizes and the measured protein concentrations, three fractions with the most EVs (between




FIG. 2. Schematic representation of the EV isolation procedure for the different sample types. EVs were isolated from cell-conditioned medium of human MSCs, tissue-conditioned medium of pig and dog NCs, and a biological fluid (human milk). NC-derived EVs and MSC-derived EVs were isolated with a combination of differential centrifugation and SEC. After SEC, EV containing fractions (8–10) were pooled based on protein content. Milk-derived EVs were isolated using differential centrifugation, SEC, and density gradient centrifugation. $n = 3$ for human and dog samples, $n = 6$ for pig samples. EVs, extracellular vesicles; MSCs, mesenchymal stromal cells; NCs, notochordal cells; SEC, size exclusion chromatography. Color images are available online.

fractions 7 and 11) were pooled per donor, yielding 1.5 mL of EV-enriched sample. The pooled samples were topped up with PBS in SW41 tubes and centrifuged at 100,000 g (65 min, 4°C; Beckman Coulter). The 100,000 g pellets of the pooled-EV fractions were resuspended in a maximum of 35 μ L PBS per donor and stored at -80°C until further use.

Lastly, to explore the possibility of DigiWest to analyze multiple markers on low protein samples and to show that the SEC fractions selected for NC-EVs indeed contained EVs, for one pig donor (3 months old), all collected SEC fractions were pooled in sets of three (fraction 2–4, 5–7, 8–10, 11–13, 14–16, 17–19, 20–22, and 23–25) to analyze the presence of the EV markers.

Human milk collection

Milk samples were donated by healthy mothers (mean age of 33 ± 2.3 years) who gave birth through vaginal delivery between 2015 and 2018 and were at a lactational stage of 3

to 7 months (with an average of 4.7 ± 2 months). The Medical Research Involving Human Subjects Act did not apply according to the Hospital Medical Research Ethics Committee. Informed consent was signed by all donors. In brief, mothers were asked to collect milk by using an electric breast pump. Milk was prevented from cooling down, and within 30 min after collection, it was depleted from cells and fat by two rounds of centrifugation at 3000 g (10 min, 22°C; Beckman Coulter Allegra X-12R) as described previously.²⁹ Cell and fat-free milk supernatants were stored at -80°C until further processing.

EV isolation from human milk

Milk-EVs were isolated from 6 mL of cell and fat-free milk supernatant according to a published protocol³⁶ with minor modifications (Fig. 2). Once thawed, 2 mL of supernatant was loaded into a 10 mL syringe (BD Biosciences) stacked with 10 mL Sepharose CL-2B (GE Healthcare) on

top of a 20 µm pore size nylon net (NY2002500; Merck Millipore). A total of three columns were used for each supernatant. Fractions of 1 mL eluate were collected.

Three milliliters EV-containing eluates (eluates 4–6) were concentrated to 1 mL using a Amicon Ultra-2 Centrifugal Filter Unit (UFC201024; Merck Millipore) centrifuged at 3000 *g* for 10–20 min at 4°C. One milliliter concentrated sample was retrieved by upside-down centrifugation at 1000 *g* for 2 min at 4°C and placed on top of a Optiprep (Axis-Shield) density gradient. Discontinuous iodixanol gradients were prepared by layering 4 mL of 40%, 4 mL of 20%, 4 mL of 10%, and 3.5 mL of 5% iodixanol in a 16.8 mL open top polyallomer tube (Beckman Coulter).

Gradient centrifugation was performed at 100,000 *g* for 18 h at 4°C using a SW32.1 Ti rotor (Beckman Coulter). Fractions of 1 mL were collected and EV-rich fractions 9 and 10, corresponding to a density of 1.01–1.18 g/mL, were pooled. Pooled fractions underwent SEC with Sepharose CL-2B and concentration in Amicon Ultra-2 Centrifugal Filter Unit at 3000 *g* at 4°C until a final sample volume of 100 µL was reached. EV samples were stored at –80°C until further use.

Protein quantification of human milk-EVs

Milk-EV samples were quantified by Qubit Protein assay kit (ThermoFisher Scientific) according to manufacturer's instructions. In brief, 5 µL of milk-EVs (lysing condition sodium dodecyl sulfate [SDS] 0.2%) was incubated with 195 µL of Qubit Working solution at room temperature in the dark for 15 min. Protein concentration was measured by using the Qubit Fluorometer 3.0 (ThermoFisher Scientific).

Lysis and quality control DigiWest

EV and positive control (MSCs, NCs, and NC-rich NP tissue) samples were diluted 1:2 in 2× lysis buffer containing 4% lithium dodecyl sulfate, 50 mM of dithiothreitol (DTT), cOmplete™ protease inhibitor and PhosSTOP™ phosphatase inhibitor (Roche), denatured at 95°C for 10 min, and homogenized by centrifugation through a QIAshredder

device (Qiagen). One microliter lysate was diluted in loading buffer (212 mM Tris, 282 mM Tris base, 1.01 mM ethylenediaminetetraacetic acid, and 50 mM DTT, 10% glycerol, 0.22 mM Coomassie brilliant blue), and applied to SDS-PAGE using a NuPAGE system (Life Technologies) with a 4–12% Bis-Tris gel. Protein was determined using a LI-COR Odyssey Classic imaging system.

Data analysis

For correct signal detection for the markers, peaks shown in the DigiWest analysis tool were assessed for several criteria. First, the minimal value of the peak height had to be at least 50. The peak area, that is, the AFI, had to be at least 100. If these criteria were met, the MW of the peak was matched with the MW reported for the respective antibody. If a shift (≤10 kDa) in MW was observed compared with the predicted MW, it was checked whether this shift was consistent in all samples. If consistent and the band at the corresponding MW was also present in the documentation of the antibody supplier, the signal for this antibody was considered to be specific for the marker.

Experimental Results





Samples and protein input for DigiWest analysis

The protein amount loaded for cell and tissue lysates was generally higher (8–10 µg protein) than for EV-samples (Table 1). The latter also depended on the EV source, for example, for MSC-EVs a considerable lower protein yield was obtained after isolation when compared with milk-EVs. Since there were considerable differences in protein yield in EV-samples between donors, either the maximum input of that donor or the maximum protein load for DigiWest (10 µg) was used.

Antibody optimization for EV characterization with DigiWest

Based on the ISEV recommended protein markers and the availability of the antibodies, 30 antibodies were selected




TABLE 1. OVERVIEW OF THE PROTEIN INPUT USED FOR DIGIWEST FOR ALL SAMPLES, SHOWN PER DONOR

| Species | Sample source | Amount of protein loaded in DigiWest (µg) | | | | | | | |
|--|-----------------------------------|---|-----|------|-------|-------|-------|-------|-------|
|  Human | MSCs (positive control) | 10 | 10 | | | | | | |
| | Milk-EVs | 8 | 8 | 8 | | | | | |
| | MSC-EVs | 2.3 | 3.3 | 3 | | | | | |
|  Dog | NCs (positive control) | 10 | 10 | | | | | | |
| | NC-EVs | 6.8 | 8 | 9.1 | | | | | |
|  Pig | NC-rich tissue (positive control) | 2.5 | 5 | 5 | | | | | |
| | NCs (positive control) | 8 | 8 | 8 | 10 | 10 | | | |
| | NC-EVs | 1.5 | 1.5 | 5.8 | 7.9 | 10 | | | |
| SEC fraction numbers | | | | | | | | | |
|  Pig | NC-EVs | 2–4 | 5–7 | 8–10 | 11–13 | 14–16 | 17–19 | 20–22 | 23–25 |
| | | 0.6 | 1.2 | 9 | 6.2 | 2.4 | 1.2 | 0.9 | 1.1 |

DigiWest analysis included the analysis of positive control samples (MSCs, NCs, and NC-rich tissue), and EV-samples. *n* = 2 for positive control samples from dog and human, *n* = 3 for positive control tissue samples from pig, *n* = 5 for cell lysates from pig, *n* = 3 for EV-samples from dog and human, *n* = 5 for EV-samples from pig, and *n* = 1 for the fractionated pig NC-EVs.

EVs, extracellular vesicles; MSCs, mesenchymal stromal cells; NCs, notochordal cells; SEC, size exclusion chromatography.

TABLE 2. LIST OF OPTIMIZED ANTIBODIES FOR EXTRACELLULAR VESICLES SAMPLES OF ALL THREE SPECIES

| Species | Human | | Dog | Pig | |
|--|---|-----|---|---|---|
| |  | |  |  | |
| EV source | Milk | MSC | NC-CM | NC-CM | |
| Target protein | Results DigiWest | | | | Antibody specifications |
| Category 1. Transmembrane or GPI-anchored proteins associated with plasma membrane/endosomes | | | | | |
| Integrin beta 1 | ✗ | ✓ | ✗ | ✓ | Transduction Laboratories 610468 |
| Sonic hedgehog | ✗ | ✗ | ✓ | ✓ | C9C5, Cell Signaling 2207 |
| CD9 | ✓ | ✗ | ✓ | ✓ | EPR2949, Abcam ab92726 |
| Category 2. Cytosolic proteins recovered in EVs | | | | | |
| TSG101 | ✓ | ✓ | ✓ | ✓ | EPR7130(B), Abcam ab125011 |
| Flotillin 1 | ✓ | ✓ | ✓ | ✓ | Clone 18, BD transduction laboratories 610820 |
| Caveolin 1 | ✓ | ✓ | ✓ | ✓ | Cell Signaling, 3238 |
| HSP70/HSC70 | ✓ | ✓ | ✓ | ✓ | N27F3-4, Enzo ADI-SPA-820 |
| HSC70 (HSPA8) | ✓ | ✓ | ✓ | ✓ | D12F2, Cell Signaling 8444 |
| Annexin II | ✓ | ✓ | ✓ | ✓ | BD Transduction Laboratories 610068 |
| GAPDH | ✓ | ✓ | ✓ | ✓ | D16H11, Cell Signaling 5174 |
| Category 3. Major components of non-EV coisolated structures | | | | | |
| S6 ribosomal protein - pS235/pS236 | ✗ | ✗ | ✗ | ✗ | Cell Signaling 2211 |
| Category 4. Transmembrane, lipid-bound, and soluble proteins associated with other intracellular compartments than PM/endosomes | | | | | |
| Keratin 8 | ✗ | ✗ | ✗ | ✗ | Cell Signaling 4548 |
| Keratin 18 | ✗ | ✗ | ✗ | ✗ | M20, Santa Cruz sc-52324 |
| Category 5. Secreted proteins recovered with EVs | | | | | |
| Fibronectin | ✓ | ✓ | ✓ | ✓ | F14, Abcam ab45688 |
| Category 6. Others of interest | | | | | |
| Enolase-1 | ✓ | ✓ | ✓ | ✓ | Cell Signaling 3810 |

All depicted antibodies were optimized on EV and positive control samples (MSCs, NCs, and NC-rich tissue) from each species. Protein markers are divided into the categories set out by the International Society for Extracellular Vesicles. ✓/✗ indicates whether the marker was or was not detected in the specific EV sample. $n=3$ for human and dog samples, $n=5$ for pig samples.

CM, conditioned culture medium; GPI, glycosylphosphatidylinositol; PM, plasma membrane.

for the characterization (Supplementary Table S1). Of this panel, 15 antibodies were successfully optimized for all three species (Table 2 and Supplementary Fig. S1). DigiWest analysis of EVs from different species and sources revealed a remarkable overlap in the presence of nine general EV markers, that is, flotillin-1, TSG101, caveolin-1, HSP70, HSPA8, annexin II, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), fibronectin, and enolase-1 (Table 1 and Fig. 3).

Three of the coisolated proteins, keratin 8, keratin 18, and S6 ribosomal protein, were undetectable in all EV-samples, but present in control samples. Sonic hedgehog (SHH) and integrin beta 1 (ITGB1) were only detected in EV-samples from two species. The tetraspanin CD9 was detected in all species, but not in MSC-EVs.

DigiWest enables the visualization of data similar to Western blotting

From the digital signals obtained from the DigiWest analysis, data can be visualized resembling traditional Western blots, so called Western blot mimics (Fig. 3). The intensity of the depicted bands in these mimics cannot be compared directly between samples and experiments, it only allows for visualization of the MW of the signal in different

samples. In general, the MW of the DigiWest signal corresponded with the predicted MW of the antibody for the different samples and species (e.g., TSG101, flotillin-1, and GAPDH; Fig. 3).

For antibodies that were predicted to detect a protein at multiple MWs because of different isoforms, differences between species/samples were observed. Caveolin-1 had a signal at 24 kDa in human milk-EVs, whereas EVs from other sources (human MSCs, pig and dog NC) only showed a signal at 21 kDa. CD9 showed a band at a much lower MW than expected. However, since this shift was consistent between all samples and a clear peak was observed in the DigiWest analysis tool at this height, the signal was considered specific. Altogether, these results indicate that DigiWest is a robust method facilitating the detection of multiple EV markers in low protein containing EV samples, independent from tissue source and species.

DigiWest allows for simultaneous detection of multiple proteins in a single EV sample

The optimized antibody panel was used to analyze the SEC fractions from pig NC-CM to confirm the presence of EVs in the fractions selected for the previous analysis and to determine the potential of DigiWest for low protein





FIG. 3. Western blot mimics of five general EV markers in the different species. For humans, EVs samples from milk and MSCs were analyzed. For dog and pig samples, EVs from NCs were analyzed. The *underlined* MW indicates the predicated MW for that marker, based on the antibody information. $n=3$ for human and dog samples, $n=5$ for pig samples. MW, molecular weight. Color images are available online.

samples. The protein quantities in SEC fractions ranged from 0.6 to 9 μg , with the first three fractions containing the least amount of protein (Table 1). Owing to too low protein amounts (<0.9 μg protein), fractions 2–4 and 23–25 were excluded from the analysis. All other fractions contained sufficient protein (>0.9 μg) to obtain a steady DigiWest signal.

An enrichment in the EV markers CD9, TSG101, flotillin-1, and caveolin-1 was detected in fractions 8–10 and 11–13 (Fig. 4a). A similar pattern was obtained for GAPDH (Fig. 4b). In contrast to the previously analyzed samples, in the SEC fractions from pig NC-CM a signal was obtained for S6 ribosomal protein in fractions 8–13 (Supplementary Fig. S2), suggesting that this protein had been coisolated.

FIG. 4. Heat map of five markers in the SEC fractions of pig NC-CM. **(a)** Profile of the AFI of four EV markers within the pooled SEC fractions. The X-mark indicates that marker was too low for peak detection in the SEC fractions. **(b)** Profile of the AFI of GAPDH within the SEC fractions. $n=1$. AFI, accumulated fluorescence intensity; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. Color images are available online.



Altogether, these results indicate that 0.9 μ g protein input was sufficient for analyzing multiple EV markers in the EV-samples used in this study. Moreover, SEC fractions 8–13 appeared to contain the most EVs according to the expression profile of general EV markers, which confirms that the right fractions were selected for DigiWest analysis of NC-EVs.

DigiWest shows overlap in identified markers with mass spectrometry

Since this is the first reported use of DigiWest for EV characterization, we compared the obtained results with published proteomics mass spectrometry data of human milk and bone marrow-derived MSC-EVs.^{29,37,38} For milk-derived EVs, the 13 proteins detected with DigiWest were, apart from caveolin 1, all detected previously by mass spectrometry analysis (Table 3).^{29,37} Of the 12 proteins detected by DigiWest analysis of MSC-EVs, all were previously identified in proteomics.³⁸ In conclusion, targeted proteomic analysis based on DigiWest shows a reasonable good overlap with mass spectrometry analysis.

Discussion

Characterization of EV preparations is essential when working with EVs in either a research or (pre-)clinical setting. The ISEV guidelines recommend the analysis of multiple protein markers in EV samples to demonstrate the presence of EVs and to get an indication on coisolated proteins. This study is the first to report the successful use of a multiplex bead-based Western blotting platform (DigiWest)²⁴ for EV characterization of EVs isolated from CM and complex biological fluids from different sources and species. The optimized antibody panel mainly entails general EV markers,³⁹ making the created panel presumably convenient for the characterization of EVs from other sources than those reported here.

The panel selected is dynamic and can be modified on the EV type or the specific characterization that is required. DigiWest is restricted by the availability of antibodies, but with the availability of many antibodies for Western blotting, a wide range of markers is possible.

Three of the optimized markers could only be used in specific species (ITGB1 and SHH) or EV sources (CD9). For ITGB1 and CD9, the absence of detection in, respectively, human milk-EVs and MSC-EV is considered to be related either to the sensitivity of the DigiWest technology or to a relatively low starting protein quantity resulting in undetectable levels. ITGB1 was previously detected in milk-EVs^{29,36} and CD9 has been shown in MSC-EVs³⁸ with mass spectrometry, a methodology considered to be more sensitive than Western blot-based techniques⁴⁰ such as DigiWest.

SHH is expressed during embryonic development in the notochord⁴¹ and, therefore, also in the cells that descent from the notochord, the NCs^{42,43} explaining SHH being NC-EV associated. Although SHH is known to be expressed during breast development, its expression in adult healthy mammary tissue is considered low.⁴⁴ The absence of SHH in human milk-EVs and MSCs may thus be tissue dependent.

In addition to showing the presence of EVs in the sample, EVs can be assessed by studying possible coisolated proteins.¹⁹ Three of such proteins, that is, keratin 8, keratin 18, and S6 ribosomal protein, were successfully validated using positive control (tissue/cell) samples but were undetectable in the majority of the studied EV samples. In the SEC fractions from the pig NC-EV donor studied, S6 ribosomal protein was detected, indicating the presence of ribosomal proteins. This observation implies impurity of the sample and that DigiWest can be used to assess coisolated proteins in EV samples.

Traditional Western blotting requires $\sim 10 \mu$ g of protein for the identification of an individual protein marker, which can be a limitation for EV analysis. DigiWest commonly employs between 5 and 20 μ g protein. It must be noted, however, that with DigiWest, this protein input can be used

TABLE 3. COMPARISON BETWEEN THE RESULTS OBTAINED FOR THE ANALYZED PROTEIN MARKERS WITH THE DIGIWEST TECHNOLOGY AND MASS SPECTROMETRY FOR HUMAN MILK-DERIVED EXTRACELLULAR VESICLES AND HUMAN BONE DERIVED-MESENCHYMAL STROMAL CELL EXTRACELLULAR VESICLES

| <i>Protein marker</i> | <i>Milk-EVs</i> | | <i>MSC-EVs</i> | |
|--|-----------------------------|--------------------------------------|-----------------------------|--------------------------------------|
| | <i>Detected in DigiWest</i> | <i>Detected in mass spectrometry</i> | <i>Detected in DigiWest</i> | <i>Detected in mass spectrometry</i> |
| Category 1. Transmembrane or GPI-anchored proteins associated with plasma membrane/endosomes | | | | |
| CD63 | ✗ | ✓ | ✗ | ✓ |
| CD81 | ✗ | ✓ | ✗ | ✓ |
| Integrin beta 1 (ITGB1) | ✗ | ✓ | ✓ | ✓ |
| Sonic hedgehog (SHH) | ✗ | ✗ | ✗ | ✗ |
| CD9 | ✓ | ✓ | ✗ | ✓ |
| EpCAM (CD326) | ✗ | ✓ | ✗ | ✗ |
| Category 2. Cytosolic proteins recovered in EVs | | | | |
| TSG101 | ✓ | ✓ | ✓ | ✓ |
| Alix | ✗ | ✓ | ✗ | ✓ |
| Flotillin 1 | ✓ | ✓ | ✓ | ✓ |
| Caveolin 1 | ✓ | ✗ | ✓ | ✓ |
| HSP70/HSC70 | ✓ | ✓ | ✓ | ✓ |
| HSC70 (HSPA8) | ✓ | ✓ | ✓ | ✓ |
| HSP90 | ✗ | ✓ | ✗ | ✓ |
| Annexin II | ✓ | ✓ | ✓ | ✓ |
| Actin, smooth muscle | ✗ | ✓ | ✗ | ✓ |
| GAPDH | ✓ | ✓ | ✓ | ✓ |
| Category 3. Major components of non-EV coisolated structures | | | | |
| S6 ribosomal protein—pS235/pS236 | ✗ | ✗ | ✗ | ✗ |
| Category 4. Transmembrane, lipid-bound, and soluble proteins associated with other intracellular compartments than PM/endosomes | | | | |
| KRT18 | ✗ | ✓ | ✗ | ✗ |
| KRT8 | ✗ | ✓ | ✗ | ✓ |
| Category 5. Secreted proteins recovered with EVs | | | | |
| WNT3A | ✗ | ✗ | ✗ | ✗ |
| CTGF | ✗ | ✗ | ✗ | ✓ |
| MFGE8 | ✓ | ✓ | ✓ | ✓ |
| Collagen 2 | ✗ | ✗ | ✗ | ✗ |
| Aggrecan | ✗ | ✗ | ✗ | ✗ |
| Fibronectin | ✓ | ✓ | ✓ | ✓ |
| Galectin-3BP | ✗ | ✓ | ✗ | ✓ |
| Category 6. Others of interest | | | | |
| CD44 | ✗ | ✓ | ✓ | ✓ |
| Mucin 1 | ✓ | ✓ | ✗ | ✗ |
| Enolase-1 | ✓ | ✓ | ✓ | ✓ |
| YWHAZ | ✓ | ✓ | ✗ | ✓ |

Protein markers are divided into the categories set out by the International Society for Extracellular Vesicles. ✓/✗ indicates whether the marker was or was not detected with the specific technique. Mass spectrometry data are obtained from the literature for comparison (milk-EVs,^{29,36} and MSC-EVs³⁸).

to test >100 antibodies,²⁴ whereas for conventional Western blotting, this protein input is used per antibody. We here show that a total of nine markers were successfully analyzed in pig NC-EV samples containing 0.9–9 µg protein input. Multiple markers in samples with a low protein content (≥1 µg) can thus be determined, whereas the minimum amount of protein required for DigiWest technology may, however, depend on the source and complexity of the samples.²⁴

Mass spectrometry analysis has gained interest in determining EV cargo because of its sensitivity and specificity compared with other techniques.⁴⁰ In retrospect analysis with the mass spectrometry analysis of MSC-EVs and milk-EVs described in the literature,^{29,37,38} there was an overlap

for 12 proteins with those identified through DigiWest. DigiWest failed in the majority of samples to demonstrate the presence of tetraspanins, proteins that were detected in a large number of milk-EV donors,^{29,36} and MSC-EV donors³⁸ through proteomic analysis (mass spectrometry).

This discrepancy can be explained by the inability of this study to successfully optimize antibodies for these markers, as these proteins were also not detected in positive control samples. This clearly shows a major limitation of the DigiWest technique that, similar to Western blotting and other techniques using antibody-based detection, still requires a working antibody for that species limiting its application.²⁴

Interestingly, DigiWest identified caveolin 1 in human milk-EVs, which was not previously detected with mass

spectrometry. Although caveolin 1 has not been described in milk-EVs, it is expressed in healthy mammary cells⁴⁵ and has an important role in EV biogenesis.⁴⁶ A possible explanation for this discrepancy between DigiWest and mass spectrometry might be the structure of caveolins. Caveolin 1 contains a highly hydrophobic central domain that forms a hairpin structure in the membrane,⁴⁷ which can be challenging for mass spectrometry analysis. Proteolytic hydrolysis of the proteins into peptides before mass spectrometry is generally performed by using trypsin. However, membrane proteins typically contain few cleavage sites for trypsin.⁴⁸ The use of trypsin for the identification of membrane proteins, such as caveolin 1, can limit the generation of peptides of suitable size for mass spectrometry identification. Therefore, the absence of caveolin 1 in human milk-EVs with mass spectrometry might be explained by the use of trypsin as protease.

Conclusions

This study shows that DigiWest is a robust method for the detection of multiple protein markers in EV samples, independent from source and species. The optimized panel entails general EV markers validated for the application in human, dog, and pig derived EV-samples and may, therefore, also be relevant for the characterization of EV samples from alternative sources. Furthermore, DigiWest has been successfully used in EV samples with a low protein content, showing the applicability of this technique for such sample types.

Although DigiWest shows a good overlap with previously obtained mass spectrometry data, DigiWest is a targeted technique for EV characterization rather than an unbiased screening of EV content. With the availability of many antibodies for Western blotting, the antibody panel can easily be tailored to individual EV sources and research questions. Altogether, this study demonstrates the relevance of the DigiWest technique for the characterization of multiple EV types in the regenerative medicine field.

Acknowledgments

The authors thank prof. An Hendrix, PhD candidates Claudio Pinheiro and Quentin Roux (Laboratory for Experimental Cancer Research—UGent) for providing support with milk-EV isolation and protein quantification.

Authors' Contributions

J.C.v.M. contributed to investigation, formal analysis, visualization, writing—original draft, and writing—review and editing. F.C.B. was involved in conceptualization, investigation, formal analysis, supervision, and writing—review and editing. T.S.B. carried out methodology, investigation, writing—original draft, and writing—review and editing. A.G. took charge of conceptualization, investigation, and writing—original draft. B.W.M.v.B. took charge of resources and writing—review and editing. M.T. carried out writing—review and editing. M.H.M.W. took charge of conceptualization and writing—review and editing. M.A.T. was in charge of conceptualization, supervision, funding acquisition, and writing—review and editing.

Disclaimer

The authors declare that none of the companies financed any part of the study nor interfered with the analyses and/or interpretation of data.

Disclosure Statement

M.A.T. is employee of NMI and NMI TT Pharma-services, which provides DigiWest analysis. Publishing this article does not lead to any financial benefit to authors.

Funding Information

This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 825925 and the Dutch Arthritis Society (LLP22). The research of A.G. was supported by the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 722148.

Supplementary Material

Supplementary Figure S1
Supplementary Figure S2
Supplementary Table S1
Supplementary Table S2

References

1. El-Kadiry AEH, Rafei M, Shammaa R. Cell therapy: Types, regulation, and clinical benefits. *Front Med (Lausanne)* 2021;8:2340; doi: 10.3389/FMED.2021.756029/BIBTEX
2. Han Y, Li X, Zhang Y, et al. Mesenchymal stem cells for regenerative medicine. *Cells* 2019;8:886; doi: 10.3390/cells8080886
3. Dodson BP, Levine AD. Challenges in the translation and commercialization of cell therapies. *BMC Biotechnol* 2015;15(1):1–15; doi: 10.1186/S12896-015-0190-4/TABLES/2
4. Driscoll D, Farnia S, Kefalas P, et al. Concise review. The high cost of high tech medicine: Planning ahead for market access. *Stem Cells Transl Med* 2017;6:1723–1729; doi: 10.1002/sctm.16-0487
5. Corbett MS, Webster A, Hawkins R, et al. Innovative regenerative medicines in the EU: A better future in evidence? *BMC Med* 2017;15(1); doi: 10.1186/S12916-017-0818-4/FIGURES/1
6. Petrus-Reurer S, Romano M, Howlett S, et al. Immunological considerations and challenges for regenerative cellular therapies. *Commun Biol* 2021;4:798; doi: 10.1038/s42003-021-02237-4
7. de Jong OG, van Balkom BWM, Schiffelers RM, et al. Extracellular vesicles: Potential roles in regenerative medicine. *Front Immunol* 2014;5; doi: 10.3389/FIMMU.2014.00608
8. Raposo G, van Niel G, Stahl PD. Extracellular vesicles and homeostasis: An emerging field in bioscience research. *FASEB Bioadv* 2021;3(6):456; doi: 10.1096/FBA.2021-00009
9. Zhang X, Liu D, Gao Y, et al. The biology and function of extracellular vesicles in cancer development. *Front Cell Dev Biol* 2021;9:3192; doi: 10.3389/FCELL.2021.777441/BIBTEX

10. Herrmann M, Diederichs S, Melnik S, et al. Extracellular vesicles in musculoskeletal pathologies and regeneration. *Front Bioeng Biotechnol* 2020;8:624096; doi: 10.3389/FBIOE.2020.624096
11. Kim HY, Kwon S, Um W, et al. Functional extracellular vesicles for regenerative medicine. *Small* 2022;18; doi: 10.1002/smll.202106569
12. Zhu X, Badawi M, Pomeroy S, et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. *J Extracell Vesicles* 2017;6(1):1324730; doi: 10.1080/20013078.2017.1324730
13. Somiya M, Yoshioka Y, Ochiya T. Biocompatibility of highly purified bovine milk-derived extracellular vesicles. *J Extracell Vesicles* 2018;7(1):1440132; doi: 10.1080/20013078.2018.1440132
14. Liu S, Wu X, Chandra S, et al. Extracellular vesicles: Emerging tools as therapeutic agent carriers. *Acta Pharm Sin B* 2022;12(10):3822–3842; doi: 10.1016/J.APSB.2022.05.002
15. Kodam SP, Ullah M. Diagnostic and therapeutic potential of extracellular vesicles. *Technol Cancer Res Treat* 2021;20; doi: 10.1177/15330338211041203
16. Claridge B, Lozano J, Poh QH, et al. Development of extracellular vesicle therapeutics: Challenges, considerations, and opportunities. *Front Cell Dev Biol* 2021;9:2307; doi: 10.3389/FCELL.2021.734720/BIBTEX
17. Ramirez MI, Amorim MG, Gadelha C, et al. Technical challenges of working with extracellular vesicles. *Nanoscale* 2018;10:881–906; doi: 10.1039/c7nr08360b
18. Ludwig N, Whiteside TL, Reichert TE. Challenges in exosome isolation and analysis in health and disease. *Int J Mol Sci* 2019;20(19); doi: 10.3390/IJMS20194684
19. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles* 2018;7(1); doi: 10.1080/20013078.2018.1535750
20. Gardiner C, Vizio DD, Sahoo S, et al. Techniques used for the isolation and characterization of extracellular vesicles: Results of a worldwide survey. *J Extracell Vesicles* 2016;5(1); doi: 10.3402/JEV.V5.32945/SUPPL_FILE/ZJEV_A_11821259_SM0001.PDF
21. Singh KK, Gupta A, Bharti C, et al. Emerging techniques of western blotting for purification and analysis of protein. *Future J Pharm Sci* 2021;7(1):1–14; doi: 10.1186/S43094-021-00386-1
22. Khatri M, Richardson LA, Meulia T. Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. *Stem Cell Res Ther* 2018;9(1):17; doi: 10.1186/s13287-018-0774-8
23. Silachev DN, Goryunov KV, Shpilyuk MA, et al. Effect of MSCs and MSC-derived extracellular vesicles on human blood coagulation. *Cells* 2019;8:258; doi: 10.3390/cells8030258
24. Treindl F, Ruprecht B, Beiter Y, et al. A bead-based western for high-throughput cellular signal transduction analyses. *Nat Commun* 2016;7(1):1–11; doi: 10.1038/ncomms12852
25. Tang Y, Zhou Y, Li HJ. Advances in mesenchymal stem cell exosomes: A review. *Stem Cell Res Ther* 2021;12(1):1–12; doi: 10.1186/S13287-021-02138-7/TABLES/5
26. Kou M, Huang L, Yang J, et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: A next generation therapeutic tool? *Cell Death Dis* 2022;13(7):1–16; doi: 10.1038/s41419-022-05034-x
27. Bach F, Libregts S, Creemers L, et al. Notochordal-cell derived extracellular vesicles exert regenerative effects on canine and human nucleus pulposus cells. *Oncotarget* 2017;8(51):88845–88856; doi: 10.18632/oncotarget.21483
28. Bach FC, Poramba-Liyanage DW, Riemers FM, et al. Notochordal cell-based treatment strategies and their potential in intervertebral disc regeneration. *Front Cell Dev Biol* 2022;9; doi: 10.3389/fcell.2021.780749
29. Zonneveld MI, van Herwijnen MJC, Fernandez-Gutierrez MM, et al. Human milk extracellular vesicles target nodes in interconnected signalling pathways that enhance oral epithelial barrier function and dampen immune responses. *J Extracell Vesicles* 2021;10(5):e12071; doi: 10.1002/JEV2.12071
30. Aarts J, Boleij A, Pieters BCH, et al. Flood control: How milk-derived extracellular vesicles can help to improve the intestinal barrier function and break the gut–joint axis in rheumatoid arthritis. *Front Immunol* 2021;12:2931; doi: 10.3389/FIMMU.2021.703277/BIBTEX
31. Prins HJ, Rozemuller H, Vonk-Griffioen S, et al. Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute for fetal bovine serum. *Tissue Eng Part A* 2009;15(12):3741–3751; doi: 10.1089/TEN.TEA.2008.0666/ASSET/IMAGES/LARGE/FIG-5.JPEG
32. Nguyen VVT, Ye S, Gkouzioti V, et al. A human kidney and liver organoid-based multi-organ-on-a-chip model to study the therapeutic effects and biodistribution of mesenchymal stromal cell-derived extracellular vesicles. *J Extracell Vesicles* 2022;11(11):12280; doi: 10.1002/JEV2.12280
33. Lee NN, Cook JL, Smith LJ, et al. A comprehensive tool box for large animal studies of intervertebral disc degeneration. *JOR Spine* 2021;(May):1–36; doi: 10.1002/jsp2.1162
34. Spillekom S, Smolders L, Arkesteijn I, et al. Increased osmolarity and cell clustering preserve canine notochordal cell phenotype in culture. *Global Spine J* 2017;4(1_suppl):s-0034-1376553-s-0034-1376553; doi: 10.1055/S-0034-1376553
35. Bach FC, de Vries SAH, Krouwels A, et al. The species-specific regenerative effects of notochordal cell-conditioned medium on chondrocyte-like cells derived from degenerated human intervertebral discs. *Eur Cell Mater* 2015;30:132–137; doi: 10.22203/ecm.v030a10
36. Vergauwen G, Dhondt B, Van Deun J, et al. Confounding factors of ultrafiltration and protein analysis in extracellular vesicle research. *Sci Rep* 2017;7(1):1–12; doi: 10.1038/s41598-017-02599-y
37. Van Herwijnen MJC, Zonneveld MI, Goerdal S, et al. Comprehensive proteomic analysis of human milk-derived extracellular vesicles unveils a novel functional proteome distinct from other milk components. *Mol Cell Proteomics* 2016;15(11):3412–3423; doi: 10.1074/mcp.M116.060426
38. Wang Z-g, He Z-y, Liang S, et al. Comprehensive proteomic analysis of exosomes derived from human bone marrow, adipose tissue, and umbilical cord mesenchymal stem cells. *Stem Cell Res Ther* 2020;11(1); doi: 10.1186/S13287-020-02032-8

39. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles* 2018;7(1); doi: 10.1080/20013078.2018.1535750
40. Pocsfalvi G, Stanly C, Vilasi A, et al. Mass spectrometry of extracellular vesicles. *Mass Spectrom Rev* 2015; doi: 10.1002/mas.21457
41. Choi KS, Lee C, Harfe BD. Sonic hedgehog in the notochord is sufficient for patterning of the intervertebral discs. *Mech Dev* 2012;129(9–12):255–262; doi: 10.1016/J.MOD.2012.07.003
42. Bach FC, de Rooij KM, Riemers FM, et al. Hedgehog proteins and parathyroid hormone-related protein are involved in intervertebral disc maturation, degeneration, and calcification. *JOR Spine* 2019;2(4); doi: 10.1002/JSP2.1071
43. Risbud MV, Schoepflin ZR, Mwale F, et al. Defining the phenotype of young healthy nucleus pulposus cells: Recommendations of the Spine Research Interest Group at the 2014 annual ORS meeting. *J Orthop Res* 2015;33(3):283–293; doi: 10.1002/JOR.22789
44. Cui W, Wang LH, Wen YY, et al. Expression and regulation mechanisms of Sonic Hedgehog in breast cancer. *Cancer Sci* 2010;101(4):927–933; doi: 10.1111/J.1349-7006.2010.01495.X
45. Wang S, Wang N, Zheng Y, et al. Caveolin-1 inhibits breast cancer stem cells via c-Myc-mediated metabolic reprogramming. *Cell Death Dis* 2020;11(6):1–16; doi: 10.1038/s41419-020-2667-x
46. Morel O, Jesel L, Freyssinet J-M, et al. The evolving role of caveolin-1: A critical regulator of extracellular vesicles. *Med Sci (Basel)* 2020;8(4):46; doi: 10.3390/MEDSCI8040046
47. Ohi MD, Kenworthy AK. Emerging insights into the molecular architecture of caveolin-1. *J Membr Biol* 2022; 255(3):375–383; doi: 10.1007/s00232-022-00259-5
48. Bender J, Schmidt C. Mass spectrometry of membrane protein complexes. *Biol Chem* 2019;400(7):813–829; doi: 10.1515/HSZ-2018-0443/ASSET/GRAPHIC/J_HSZ-2018-0443_FIG_003.JPG

Address correspondence to:
 Marianna A. Tryfonidou, Prof. Dr.
 Department of Clinical Sciences
 Faculty of Veterinary Medicine
 Utrecht University
 Yalelaan 108
 3584 CM Utrecht
 the Netherlands

E-mail: m.a.tryfonidou@uu.nl

Received: March 20, 2023

Accepted: June 21, 2023

Online Publication Date: August 22, 2023